Skip to main content
VCbacked
Log inGet Started

Re-Aim Therapeutics

Headington, United Kingdom

Re‑Aim Therapeutics is a biotech start‑up developing functional cures for T cell–mediated autoimmune diseases.

$9.4M raised
May 2026
Seed

Top Investors

Oxford Science EnterprisesSyncona Partners LLP

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Re-Aim Therapeutics

How much funding has Re-Aim Therapeutics raised?
Re-Aim Therapeutics has raised $9.4M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Who are Re-Aim Therapeutics's investors?
Re-Aim Therapeutics's investors include Oxford Science Enterprises, Syncona Partners LLP.
Where is Re-Aim Therapeutics headquartered?
Re-Aim Therapeutics is headquartered in Headington, United Kingdom.
What does Re-Aim Therapeutics do?
Re‑Aim Therapeutics is a biotech start‑up developing functional cures for T cell–mediated autoimmune diseases.
What stage is Re-Aim Therapeutics at?
Re-Aim Therapeutics is at the Seed stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Re-Aim Therapeutics — Funding & Investors." VCBacked, May 18, 2026, https://www.vcbacked.co/company/re-aim-therapeutics. Accessed July 2, 2026.
APA
VCBacked. (2026). Re-Aim Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/re-aim-therapeutics
Wikipedia (cite web)
{{cite web |title=Re-Aim Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/re-aim-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .